Routine cardiac monitoring, dose modification or cessation of anticancer therapies, and pharmacologic treatment of early cardiotoxicity all contribute to improved cardiac outcomes in patients with HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.